Literature DB >> 31620219

Second-Generation FGFR Inhibitors for the Treatment of Cancers Harboring Mutated FGFRs.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2019        PMID： 31620219      PMCID： PMC6792156          DOI： 10.1021/acsmedchemlett.9b00427

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

1.  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

Authors:  Xiaoyun Lu; Hao Chen; Adam V Patterson; Jeff B Smaill; Ke Ding
Journal:  J Med Chem       Date:  2018-11-16       Impact factor: 7.446

Review 2.  Recent developments and advances of FGFR as a potential target in cancer.

Authors:  Wen-Jun Xue; Ming-Tao Li; Lin Chen; Li-Ping Sun; Yu-Yan Li
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

Review 3.  A FGFR1 inhibitor patent review: progress since 2010.

Authors:  Tao Yu; Yanyan Yang; Yan Liu; Yinfeng Zhang; Hong Xu; Mengpeng Li; Murugavel Ponnusamy; Kun Wang; Jian-Xun Wang; Pei-Feng Li
Journal:  Expert Opin Ther Pat       Date:  2016-12-26       Impact factor: 6.674
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.